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Abstract
Objectives:	 Previous	 work	 from	 this	 group	 has	 demonstrated	 that	 melatonin	 (MLT)	 is	 capable	 of
signi icantly	altering	the	growth	and	viability	of	oral	cancer	cell	lines.	The	objective	of	this	study	was
to	explore	the	receptors	that	may	modulate	MLT	effects	in	oral	cancers.
Methods:	 Polymerase	 Chain	 Reaction	 (PCR)	 primers	 speci ic	 for	 the	 primary,	 cell-surface	 MLT
receptors	 (MT1	&	MT2)	were	obtained	and	used	 to	analyze	 the	mRNA	expression	 in	CAL27,	SCC15
and	SCC25	oral	cancer	cell	lines.	Extracted	RNA	following	MLT	administration	was	also	analyzed.
Results:	Expression	of	the	primary	MLT	receptor	MT1	was	absent	in	all	cell	lines,	although	expression
of	the	secondary	receptor	(MT2)	was	observed.	MLT	administration	within	the	physiologic	range	was
suf icient	 to	 induce	 MT1	 expression	 in	 all	 cell	 lines,	 suggesting	 the	 MT2	 receptor	 may	 initially
facilitate	 this	 process.	 Saturation	 of	 both	 MT1	 and	 MT2	 receptors	 observed	 within	 the
supraphysiologic	ranges	correlated	with	the	induction	of	apoptosis-related	caspase	signaling	and	the
activation	of	the	intranuclear	MLT	receptor	RZR.
Conclusions:	This	may	be	the	 irst	study	to	demonstrate	the	down-regulation	of	MT1	mRNA	in	oral
cancers,	 as	 well	 as	 novel	 evidence	 of	 the	 speci ic	 role	 of	 melatonin	 and	 the	 cognate	 receptors	 in
modulating	oral	cancer	growth.
Keywords:	Oral	Cancer;	Melatonin.
Introduction
Melatonin	 (MLT)	 is	a	hormone	 largely	produced	by	 the	pineal	gland	 in	 regular	daily	cycles	 in	most
mammals	 and	 humans,	 in	 particular	 [1].	 Although	 melatonin	 may	 be	 intricately	 involved	 in	 the
regulation	 of	 many	 diverse	 physiological	 processes,	 the	 most	 widely	 recognized	 and	 frequently
studied	 is	 the	 role	 of	 MLT	 in	 the	 regulation	 of	 the	 sleep-wake	 cycle	 [2].	 Although	 epidemiologic
evidence	 has	 suggested	 that	 disruption	 of	 the	 sleep-wake	 cycle,	 frequently	 encountered	with	 shift
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workers,	may	 be	 linked	with	MLT	 dysregulation	 and	 increased	 risk	 for	 some	 cancers–more	 recent
evidence	has	suggested	that	melatonin	has	more	speci ic	physiologic	and	pathologic	functions	speci ic
to	the	oral	cavity	[3-5].
For	example,	recent	studies	have	suggested	melatonin	and	disruption	of	melatonin-speci ic	pathways
may	be	a	critically	important	factor	that	increases	risk	of	oral	disorders,	and	more	speci ically	for	oral
cancer	[6].	In	addition,	new	evidence	has	suggested	that	silencing	and	down-regulation	of	melatonin
receptors	may,	in	fact,	be	a	common	feature	of	many	oral	cancers	[7-9].	Recent	studies	from	this	group
have	now	demonstrated	that	administration	of	melatonin	at	physiologically-relevant	concentrations
can	inhibit	the	growth	of	oral	cancers	in	vitro,	although	these	studies	did	not	evaluate	any	effects	on
melatonin	receptors,	such	as	silencing	or	down-regulation	[10].
On	the	basis	of	this	information,	the	primary	objective	of	the	current	study	involved	the	examination
of	the	expression	of	the	cell-surface,	membrane-bound	melatonin	receptors	MT1	and	MT2,	as	well	as
the	intracellular	receptor	RZR	in	oral	cancer	cell	lines.	In	addition,	the	experimental	administration	of
melatonin	 at	 physiologic	 and	 supraphysiologic	 (supplementation	 equivalent)	 concentrations	 were
evaluated	with	 the	speci ic	aim	of	analyzing	changes	 to	MT1,	MT2	and	RZR	expression	 to	correlate
with	the	observed	changes	to	cellular	behavior.
Materials	and	Methods
Cell	culture	and	cell	lines
The	human	oral	 squamous	 cell	 carcinoma	 lines,	 SCC15	 (CRL-1623),	 SCC25	 (CRL-1628),	 and	CAL27
(CRL-2095)	were	obtained	from	American	Type	Culture	Collection	(ATCC:	Manassas,	VA).	CAL27	cells
were	maintained	in	Dulbecco’s	Modi ied	Eagle’s	Medium	(DMEM)	with	4.0	mM	L-Glutamine	adjusted
to	 contain	 3.7	 g/L	 sodium	 bicarbonate,	 4.5	 g/L	 glucose,	 and	 110	mg/L	 sodium	pyruvate,	 obtained
from	HyClone	 (Logan,	UT).	SCC15	and	SCC25	cells	were	maintained	 in	a	1:1	mixture	of	DMEM	and
Ham’s	F12	medium	obtained	from	HyClone	(Logan	UT)	with	2.5	mM	L-Glutamine,	modi ied	to	contain
15	mM	4-2-hydroxyethyl-1-piperazineethanesulfonic	acid	(HEPES),	0.5	mM	sodium	pyruvate,	and	1.2
g/L	 sodium	 bicarbonate.	 All	 cell	 culture	 media	 was	 supplemented	 with	 1%	 Penicillin	 (10,000
units/mL)-Streptomycin	(10,000	ug/mL)	solution	and	10%	fetal	bovine	serum	(FBS)	obtained	from
HyClone	(Logan,	UT).	Cells	were	cultured	in	75	cm2	BD	Falcon	tissue-culture	treated	 lasks	(Bedford,
MA)	at	37°C	and	5%	CO2	in	humidi ied	chambers.
Materials
Melatonin	 (N-acetyl-5-methoxy-tryptamine,	 MLT)	 was	 obtained	 from	 GNC	 Preventive	 Nutrition®
(Pittsburgh,	 PA).	 Cellular	 assays	 were	 performed	 in	 the	 appropriate	 complete	 media,	 with	 and
without	the	addition	of	MLT	(10,	50	and	100	pg/mL).	This	concentration	range	approximates	normal
human	 physiologic	 serum	 concentrations	 (10.6	 ±	 1.7	 –	 94.8	 ±	 22.6	 pg/mL)	 [11,12].	 In	 addition,
supraphysiologic	 concentrations	 of	 MLT	 were	 also	 utilized,	 to	 approximate	 serum	 and	 saliva
concentrations	 of	 melatonin	 administered	 as	 an	 over-the-counter	 supplement	 (0.2	 –	 10	 ug/mL)
[11,12].
Proliferation
Proliferation	 assays	 were	 performed	 in	 the	 appropriate	 complete	 media,	 with	 and	 without	 the
addition	of	MLT,	prior	 to	 the	start	of	each	experimental	assay.	 In	brief,	 cells	were	plated	 in	Corning
Costar	 high-throughput,	  lat	 bottom,	 tissue	 culture-treated	 96-well	 assay	 plates	 (Corning,	 NY)	 at	 a
concentration	of	1.2	x	105	cells	per	well,	which	roughly	approximates	30-40%	con luence	per	well	at
the	onset	of	each	assay.	Proliferation	was	subsequently	measured	after	three	days.	In	brief,	cultured
cells	were	 ixed	after	72	hours,	or	day	3	(d3),	using	50	uL	of	10%	buffered	formalin	for	24	hours	at
room	temperature,	and	were	subsequently	processed	as	follows:	liquid	media	(containing	formalin)
was	aspirated	in	a	chemical	fume	hood,	cells	were	subsequently	stained	using	50	uL	of	crystal	violet
1%	aqueous	solution	(Fisher	Scienti ic:	Fair	Lawn,	NJ)	for	20	minutes	at	room	temperature.	The	stain
was	then	aspirated	and	wells	were	then	washed	with	100	uL	of	1X	phosphate-buffered	saline	(PBS)
solution	 for	one	 (1)	minute,	 followed	by	aspiration.	The	 relative	 absorbance	of	 each	well	was	 then
measured	 at	 630	 nm	 using	 a	 Bio-Tek	 ELx808	 microplate	 reader	 (Winooski,	 VT).	 The	 change	 in
proliferation,	measured	as	the	change	in	absorbance	between	day	3	and	day	1	(d3-d1)	was	calculated
and	 compared	 with	 baseline	 controls	 (cells	 receiving	 media	 with	 no	 melatonin).	 The	 data	 were
analyzed	and	graphed	using	Microsoft	Excel	(Redmond,	WA)	and	SPSS	(Chicago,	IL).	Three	separate,
independent	 replications	 of	 each	 experimental	 condition	 (physiologic,	 supraphysiologic)	 were
performed	 on	 each	 cell	 line	 by	 the	 study	 authors	 in	 random	 order	 over	 the	 course	 of	 three
consecutive	weeks.
RT-PCR:	Melatonin	receptor	expression
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To	determine	whether	the	observed	effects	of	melatonin	on	proliferation	or	viability	were	associated
with	changes	to	MT1,	MT2	or	RZR	expression,	RNA	was	isolated	from	1.5	×	107	cells	from	all	cell	lines
at	72	hours	after	growth	inhibitory	maximum	(GIMAX)	MLT	administration	from	both	the	physiologic
and	supraphysiologic	range	(100	pg/mL	and	10	mg/mL)	using	ABgene	Total	RNA	Isolation	Reagent
(Epsom,	 Surrey,UK)	 and	 the	 procedure	 recommended	 by	 the	 manufacturer	 [10].	 RT-PCR	 was
performed	with	the	ABgene	Reverse-iT	One-Step	RT-PCR	Kit	(ReadyMix	Version)	and	a	Mastercycler
gradient	 thermocycler	 (Eppendorf:	 Hamburg,	 Germany).	 The	 following	 primers	 for	MT1,	MT2	 and
RZR,	were	synthesized	by	SeqWright	(Houston,	TX)	[13,14]:
MT1	forward	primer,	TGGCATATAGGTTGCAGTCTCGG;
MT1	reverse	primer,	TGTTCTGTAGGCTTGGGCAGTTG;
MT2	forward	primer,	ACATGGAAGCGAATCAATGGACTC;
MT2	reverse	primer,	AAGGACTCAAATTCTGTTGCCACC;
RZR	forward	primer,	GATATTGGGGAACAACTGGAC;
RZR	reverse	primer,	CATGTCATCATCCAGTTTGCA;
In	brief,	one	µg	of	template	(total)	RNA	was	used	for	each	reaction.	The	reverse	transcription	step	ran
for	 30	minutes	 at	 47°C,	 followed	 by	 denaturation	 for	 2	minutes	 at	 94°C.	 Thirty	  ive	 ampli ication
cycles	were	run,	consisting	of	20	second	denaturation	at	94°C,	30	seconds	of	annealing	at	58°C,	and
6.5	minutes	of	extension	at	72°C.	Final	extension	was	run	 for	5	minutes	at	72°C.	Reaction	products
were	 separated	 by	 gel	 electrophoresis	 using	 Reliant	 4%	 NuSieve	 R3:1	 Plus	 Agarose	 gels	 (Lonza:
Rockland,	 ME).	 Bands	 were	 visualized	 by	 UV	 illumination	 of	 ethidium-bromide-stained	 gels	 and
captured	 using	 a	 Kodak	 Gel	 Logic	 100	 Imaging	 System	 and	 1D	 Image	 Analysis	 Software	 (Eastman
Kodak:	Rochester,	NY).	Quanti ication	of	RT-PCR	band	densitometry	was	performed	using	Adobe	(San
Jose,	CA)	Photoshop	imaging	software,	Image	Analysis	tools.
Results	and	Discussion
Growth	of	SCC25,	SCC15	and	CAL27	oral	cancer	cell	lines,	with	and	without	the	addition	of	MLT,	was
assessed	for	comparison	with	the	expression	of	MT1,	MT2	and	RZR	(Figure	1).	More	speci ically,	the
control	 cells	 (no	MLT)	 increased	 in	number	by	approximately	one	 third	 (31.5%,	33.2%	and	39.1%,
respectively)	 (Fig.	1A).	An	assessment	by	RT-PCR	 from	extracted	RNA	revealed	 the	absence	of	MT1
mRNA	in	all	three	cell	lines,	although	mRNA	speci ic	for	MT2	was	observed	(Fig.	1B).
The	administration	of	MLT	at	the	previously	determined	growth	inhibitory	maximum	(GIMAX)	of	100
pg/mL	within	the	normal	physiologic	range	(Phys)	was	suf icient	to	inhibit	SCC25	growth	by	-16.1%,
SCC15	y	-36.5%,	and	CAL27	by	43.1%	(Fig.	1C).	Furthermore,	the	addition	of	MLT	at	this	physiologic
concentration	was	 associated	with	 a	 slight	 up-regulation	 of	MT2	mRNA	 expression,	 as	well	 as	 the
introduction	of	MT1	mRNA	expression	(Fig.	1D).
Administration	of	MLT	at	concentrations	that	approximate	the	GIMAX	for	the	supraphysiologic	dose
(Supr)	 observed	 among	 those	 taking	 oral	 supplements	 also	 inhibited	 SCC25	 (-42.9%),	 SCC15
(-58.2%)	and	CAL27	(-71.3%)	growth	(Fig.	1E).
Farnoush	et	al.	Figure	1.	Growth	of	SCC25,	SCC15	and	CAL27	oral	cancer	cell	lines,	with	and	without
the	addition	of	MLT	in	both	physiologic	(Phys)	and	supraphysiologic	(Supr)	concentrations	using	cell
surface,	membrane-bound	receptors	MT1	and	MT2.
A	marked	up-regulation	 in	both	MT1	and	MT2	mRNA	expression	was	also	observed	 (Fig.	1F).	This
increase	ranged	between	15-fold	(CAL27:	MT1;	SCC25:	MT2)	and	30-fold	(SCC25:	MT1;	CAL27:	MT2).
As	MLT	 is	 an	 amphipathic	 hormone	 that	 possesses	 the	 ability	 to	 bind	 both	 cell	 surface	 as	well	 as
intracellular	receptors,	the	expression	of	the	intracellular	receptor	RZR	was	also	assessed	(Figure	2).
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Figure	2.	Expression	of	the	intracellular	receptor	RZR	using	SCC25,	SCC15	and	CAL27	oral	cancer	cell
lines,	with	and	without	 the	addition	of	MLT	in	both	physiologic	(Phys)	and	supraphysiologic	(Supr)
GIMAX	concentrations.
These	 analyses	 revealed	 that	RZR	 is	 not	 actively	 transcribed	 in	 either	 SCC25	or	CAL27	 cells	 under
MLT-free	conditions,	although	expression	in	SCC15	cells	was	noted	(Fig.	2A).	Administration	of	MLT	at
physiologically	relevant	concentrations	induced	expression	of	RZR	in	CAL27	cells	but	not	SCC25	cells,
while	 SCC15	 expression	was	 slightly	 down-regulated.	 However,	 supraphysiologic	 concentrations	 of
MLT	were	the	only	concentration	tested	that	induced	RZR	expression	in	SCC25	cells.	Moreover,	RZR
expression	in	both	SCC15	and	CAL27	cells	was	substantially	increased.
As	previous	studies	from	this	group	demonstrated	that	only	supraphysiologic	concentrations	of	MLT
induced	 the	 expression	 of	 key	 apoptosis	 regulatory	 genes,	 Caspase-2	 and	 Caspase-3,	 the	 relative
expression	of	the	intracellular	RZR	receptor,	graphed	on	the	X-axis,	was	plotted	against	the	expression
of	these	apoptosis-speci ic	products	on	the	Y-axis	for	comparison	(Fig.	2B).	These	analyses	revealed
that	 the	 relative	 abundance	 of	 RZR	mRNA	 transcription	was	 strongly	 associated	with	 activation	 of
Caspase-2	and	Caspase-3	expression	in	all	three	cell	lines	(R=0.731).
When	 combined,	 these	 data	 strongly	 suggest	 an	 interconnected	 and	 complex	 relationship	 between
MLT	administration	and	MLT	receptor	activation	(Figure	3).	For	example,	MT1	expression	appears	to
be	 suppressed	 in	 these	 oral	 cancer	 cell	 lines,	 although	 MT2	 expression	 was	 still	 observed.
Administration	of	MLT	within	 the	normal	physiologic	concentration	was	suf icient	 to	 induce	an	up-
regulation	 of	 MT2	 expression,	 while	 MT1	 expression	 appeared	 to	 be	 rescued.	 In	 addition,	 the
apparent	 saturation	 of	 both	MT2	 and	MT1	 receptors	with	 the	 supraphysiologic	 concentration	was
suf icient	to	allow	consequent	membrane	crossing	and	direct	 intracellular	transport	of	MLT	to	bind
with	 and	 up-regulate	 expression	 of	 the	 RZR	 receptor.	 Finally,	 this	 activation	 of	 RZR	 appears	 to	 be
suf icient	to	induce	expression	of	apoptosis-speci ic	regulators	Caspase-2	and	Caspase-3,	which	also
appeared	 to	 exhibit	 expression	 strongly	 correlated	with	RZR	 expression.	 concentrations	 associated
with	 supraphysiolgic	 dosages.	 This	 activation	 of	 RZR	 appeared	 to	 be	 strongly	 correlated	 with
activation	 of	 the	 apoptosis-speci ic	 Caspase	 initiation	 pathway	 (Caspase-2,	 Caspase-3).	 This	 may
suggest	 that	 only	 concentrations	 of	 MLT	 commensurate	 with	 supplementation	 are	 suf icient	 to
saturate	the
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Conclusions
The	primary	purpose	of	 this	study	was	 to	explore	 the	expression	of	 the	membrane-associated	MLT
receptors	MT1	and	MT2,	as	well	as	the	intracellular	receptor	RZR	in	the	context	of	previous	results
that	suggested	MLT	administration	at	physiologic	and	supraphysiologic	concentrations	was	suf icient
to	 inhibit	 growth	 of	 oral	 cancer	 cell	 lines	 [10].	 The	 main	  indings	 of	 this	 project	 suggest	 that
expression	of	at	 least	one	MLT	receptor,	MT1,	was	suppressed	in	all	three	cell	 lines	–	although	MT2
expression	remained	intact.	Moreover,	the	effects	of	MLT	administration	appeared	to	function	through
the	MT2	receptor,	as	the	physiologic	dose	of	MLT	was	suf icient	to	up-regulate	expression	of	MT2,	as
well	 as	 to	 induce	 expression	 of	 MT1.	 This	 may	 suggest	 that	 transcriptional	 suppression	 of	 MT1
expression	may	not	only	be	reversible	but	may	also	be	dependent	upon	the	activation	of	MT2	through
its	activation	by	MLT.
Interestingly,	 expression	 of	 the	 intracellular	 receptor	 RZR	 did	 not	 appear	 to	 be	 activated	 by
physiologically	 relevant	 concentrations	 of	 MLT,	 but	 were	 signi icantly	 up-regulated	 by	 the	 super
saturation	cell	surface	receptors	in	order	to	facilitate	the	cross-membrane	passage	of	MLT	to	directly
activate	the	intracellular	RZR	receptor.
These	phenomena	are	 consist	with	other	 similar	biphasic	 effects	 observed	 in	other	 studies	of	MLT
demonstrating	 that	 only	 the	 saturation	 of	 cell	 surface	MLT	 receptors	 allowed	 excess	MLT	 to	move
along	 the	 concentration	 gradient	 directly	 into	 the	 cell,	 subsequently	 binding	 the	 alternative
intracellular	 ligands	 [15-17].	 However,	 these	 results	 also	 appear	 to	 con irm	 previous	 observations
that	 although	 apoptosis	 may	 be	 induced	 only	 at	 the	 supraphysiologic	 supplementation
concentrations,	 even	 the	 lowest	 concentrations	 of	 physiologically	 relevant	 concentrations	 were
suf icient	to	activate	MT2	expression	and	to	recover	MT1	expression	in	all	cell	lines	evaluated.
Although	a	number	of	clinical,	biomedical	and	epidemiologic	 investigations	have	provided	evidence
that	MLT	may	have	signi icant	effects	on	oral	cancer	risk,	progression	and	even	mortality,	this	study
provides	novel	information	about	the	receptors	and	associated	mechanisms	that	may	be	involved	in
the	cellular	response	of	oral	cancers	to	MLT	administration.	This	study	may	the	 irst	to	demonstrate
that	MT1	expression,	lost	in	many	oral	cancers,	may	be	recovered	with	MLT	administration,	an	effect
that	could	prove	useful	for	complementary	and	alternative	therapies	for	oral	cancer.	Finally,	this	study
provided	 initial	 data	 to	 suggest	 that	 the	 induction	 of	 apoptosis	 following	 supraphysiologic	 MLT
administration	 may	 be	 correlated	 with	 RZR	 expression,	 suggesting	 that	 this	 pathway	 may	 be	 an
important	 and	 critical	 interlocutor	 that	 functions	 to	 activate	 these	 pathways	 in	 at	 least	 these	 oral
cancer	lines.	Future	studies	that	investigate	these	receptors,	pathways	and	the	mechanisms	involved
in	 their	 control	may	prove	 indispensible	 to	oral	health	 researchers	 and	oncologists	who	 search	 for
new	methods	to	control	or	inhibit	the	growth	and	spread	of	oral	cancers.
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hormone	 melatonin	 binds	 and	 activates	 an	 orphan	 of	 the	 nuclear	 receptor	 superfamily.	 J	 Biol
Chem:18;	269(46):	28531-28534.
Cucina	A,	Proietti	S,	D’Anselmi	F,	Coluccia	P,	Dinicola	S,	et	al.	(2009)	Evidence	for	a	biphasic	apoptotic
pathway	induced	by	melatonin	in	MCF-7	breast	cancer	cells.	J	Pineal	Res	46(2):	172-180.
Mao	 L,	 Dauchy	 RT,	 Blask	 DE,	 Slakey	 LM,	 Xiang	 S,	 et	 al.	 (2012)	 Circadian	 gating	 of	 epithelial-to-
mesenchymal	 transition	 in	 breast	 cancer	 cells	 via	melatonin-regulation	 of	 GSK3ß.	Mol	 Endocrinol,
26(11):	1808-1820.
Wang	J,	Xiao	X,	Zhang	Y,	Shi	D,	Chen	W,	et	al.	(2012)	Simultaneous	modulation	of	COX-2,	p300,	Akt,	and
Apaf-1	 signaling	by	melatonin	 to	 inhibit	proliferation	and	 induce	apoptosis	 in	breast	 cancer	 cells.	 J
Pineal	Res	53(1):	77-90.
              Social Media Contact Us
BIO ACCENT GROUP LLC
Openaccess by Bioaccent is licensed under a Creative Commons
Attribution 4.0 International License.
Based on a work at http://bioaccent.org/. 
8/2/2017 Bioaccent Online Publishing
https://bioaccent.org/cancer-sciences/cancer-sciences03.php 7/7
   
19C Trolley Square
Wilmington, DE 19806
Mail: info@bioaccent.org
Copyright © 2014 - All Rights Reserved - Bioaccent Bioaccent Group LLC 
